The short version
- A 2013 meta-analysis of 10 randomised trials in 543 patients with type 2 diabetes found cinnamon reduced fasting plasma glucose by 24.59 mg/dL, with heterogeneity between trials running from I² 66.5% to 94.72%.
- The 2012 Cochrane review of 10 trials in 577 participants judged the effect of cinnamon on fasting blood glucose inconclusive and found insufficient evidence to support its use in diabetes.
- Neither review found a significant effect on HbA1c; the 2013 pooled estimate was -0.16% with a confidence interval of -0.39% to 0.02%.
- Cassia cinnamon contains coumarin, for which a 2010 review derived a tolerable daily intake of 0.1 mg per kilogram of body weight based on human data showing a subgroup with unusually high susceptibility to liver effects.
- That review's consumption survey found heavy consumers of cassia cinnamon can reach a daily coumarin intake equal to the entire tolerable daily intake from food alone.
Here is a small puzzle in the evidence base that nobody selling cinnamon capsules will hand you.
In 2012, Cochrane published a review of cinnamon in diabetes: ten randomised trials, 577 participants, mostly cassia cinnamon at a mean dose of 2 g a day for four to sixteen weeks. Their conclusion on fasting blood glucose was inconclusive, with no significant difference in HbA1c, serum insulin or post-meal glucose, and insufficient evidence overall.
In 2013, a different group published in Annals of Family Medicine: ten randomised trials, 543 patients, doses from 120 mg to 6 g a day for four to eighteen weeks. Their conclusion on fasting plasma glucose was a reduction of 24.59 mg/dL, with a confidence interval from -40.52 to -8.67. Total cholesterol fell 15.60 mg/dL, LDL 9.42, triglycerides 29.59. HDL rose 1.66.
Same spice, roughly the same trials, one year apart, opposite headlines.
How both papers can be right
Look at what the 2013 authors said about their own numbers. Heterogeneity was high for every analysis except HDL, with I² running from 66.5% to 94.72%. An I² above 90 means the trials being averaged were not really measuring the same thing. The reviewers wrote that this high degree of heterogeneity may limit the ability to apply the results to patient care, because the preferred dose and duration are unclear.
That is a meta-analysis reporting a number and then telling you not to lean on it. Cochrane, applying stricter inclusion rules and a harsher read of trial quality — risk of bias was high or unclear in all but two of their ten trials — declined to average the disagreement at all.
So the reconciliation is not that one team was wrong. It is that a genuine but inconsistent effect looks like a positive pooled estimate under one set of rules and looks like noise under another.
The number that did not move
Both reviews agree on one thing, and it is the important one. HbA1c did not change. The 2013 meta-analysis found -0.16%, confidence interval -0.39% to 0.02%, not significant. Cochrane found no significant difference either.
Fasting glucose is a single morning snapshot. HbA1c reflects roughly three months of average glycaemia. An intervention that shifts the snapshot but leaves the three-month average untouched is telling you something specific: whatever is happening is not big enough, or not durable enough, to show up in the measure that integrates over time.
If you take one thing from this article, take that distinction. It applies well beyond cinnamon, and it is the single most useful filter for reading blood-sugar marketing. Chromium has the same problem in reverse — a real HbA1c effect, but only in people with diagnosed diabetes and nothing in anyone else.
The coumarin question, which is not scaremongering
Nearly all the cinnamon in supermarkets and in most capsules is cassia, not Ceylon. Cassia cinnamon contains coumarin, a plant compound with hepatotoxic properties.
A 2010 review in Molecular Nutrition and Food Research derived a tolerable daily intake for coumarin of 0.1 mg per kilogram of body weight, and did so using human clinical data from patients treated with coumarin as a drug — data which revealed a subgroup of people considerably more susceptible to liver effects than the animal species previously studied. The cause of that susceptibility is not known. The authors also ran a telephone survey of more than 1,000 people in Germany during the Christmas baking season and concluded that heavy consumers of cassia cinnamon can reach a daily coumarin intake corresponding to the entire tolerable daily intake.
That is from food. A daily capsule of concentrated cassia extract is a different exposure again, taken every day of the year rather than in December. Nobody should panic about a cinnamon latte. But a chronic, concentrated, unmeasured daily dose of a compound with a defined TDI and a known susceptible subgroup is a reasonable thing to be conservative about, and it is why we do not sell it.
What we'd actually tell you
Cinnamon on your oatmeal is a good idea for the reason it has always been a good idea: it makes plain food taste like something, which is worth more to your eating pattern over a year than a 24 mg/dL confidence interval. Ceylon if you use a lot of it.
Capsules are a different proposition. You would be buying an effect that two competent review teams could not agree existed, on a marker that does not carry through to HbA1c, in a form that concentrates the one compound in the spice worth limiting.
If your glucose genuinely needs attention, that is a doctor and a lab panel, not a spice. Type 2 diabetes and prediabetes are diagnoses and they are managed, not supplemented. And if you are the kind of person who wants to watch what your own glucose does after meals, a continuous glucose monitor will give you far more data than a cinnamon trial ever did — along with the standing temptation to read meaning into every bump, which is a separate problem worth understanding before you strap one on.
Good questions
Does cinnamon lower blood sugar?
Sometimes, in some trials, in people with type 2 diabetes. One meta-analysis found a 24.59 mg/dL drop in fasting glucose; the Cochrane review published a year earlier called the same evidence inconclusive. Both agree HbA1c did not change, which means the effect does not carry through to the measure that reflects months rather than one morning.
How much cinnamon would I need to take?
Nobody has established that, and the reviewers say so. Trials used anywhere from 120 mg to 6 g a day for four to eighteen weeks, and the authors of the positive meta-analysis noted that the preferred dose and duration remain unclear. When a literature cannot name a dose after ten trials, that is a sign the effect is not robust enough to titrate.
Is cinnamon bad for your liver?
Cassia cinnamon contains coumarin, which has hepatotoxic properties, and human data identified a subgroup of people unusually susceptible to it. The tolerable daily intake is 0.1 mg per kilogram of body weight, and heavy cassia users can reach it from food alone. Occasional culinary use is not the concern; a concentrated daily capsule taken for years is worth more caution.
Is Ceylon cinnamon better than cassia?
For coumarin exposure, yes — cassia is the variety flagged as the main dietary source in the risk assessment work. For glucose, the trials mostly used cassia, so switching to Ceylon means you are taking a different preparation from the one that was studied. If you cook with a lot of cinnamon, Ceylon is the sensible default.
Can I take cinnamon instead of my diabetes medication?
No. Cochrane found insufficient evidence to support cinnamon in type 1 or type 2 diabetes, and neither review found an HbA1c effect. Diabetes medication is prescribed and monitored for reasons that a spice does not address. If you want to discuss reducing a dose, that conversation happens with your prescriber and a lab panel.
Why doesn't LUVO sell a cinnamon supplement?
Because we could not write an honest product page for it. The efficacy evidence is contradictory between two competent reviews, the marker that matters clinically does not move, and the concentrated cassia form raises a coumarin exposure question we would then have to caveat. That is three strikes, and a spice rack solves the same problem better.
Sources
- Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Ann Fam Med, 2013. View study
- Leach MJ, Kumar S. Cinnamon for diabetes mellitus. Cochrane Database Syst Rev, 2012. View study
- Abraham K, Wöhrlin F, Lindtner O, Heinemeyer G, Lampen A. Toxicology and risk assessment of coumarin: focus on human data. Mol Nutr Food Res, 2010. View study
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
